MG Therapies Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

MG Therapies General Information


Developer of an in-clinic device designed to deliver treatments for dry eye syndrome and meibomian gland dysfunction. The company's MGrx device offers three effective clinical treatments such as Lid Debridement, Gland Expression and Anti-inflammatory Cold Therapy, enabling dry eye syndrome patients to experience relief from efficacious treatments at a quarter of the cost of the market incumbent.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Therapeutic Devices
Primary Office
  • San Diego, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MG Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 25-Jul-2017 Completed Startup
To view MG Therapies’s complete valuation and funding history, request access »

MG Therapies Executive Team (1)

Name Title Board Seat Contact Info
David McMahon Chief Executive Officer
To view MG Therapies’s complete executive team members history, request access »

MG Therapies Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EvoNexus Accelerator/Incubator 000 0000 000000 0
To view MG Therapies’s complete investors history, request access »